700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Paula Francezca C Padua|
|St. Luke’s Medical Center, Philippines|
|ScientificTracks Abstracts: Pediat Therapeut|
|Objective: (1) To present a case of venolymphatic malformation and OK-432 as its management (2) To discuss the mechanism of action of OK-432 in the treatment of venolymphatic malformations (3) To discuss the known complications of OK-432 in the treatment of venolymphatic malformations Design: Case Report Setting: Tertiary Hospital in Metro Manila Case Report: A 4 year old male, presenting with a right facial and cervicothoracic mass, consulted and given Picibanil (OK-432) as trial treatment for 2 doses. A local inflammatory response was observed after the first dose. However, the patient exhibited a systemic inflammatory response after the 2nd dose. Conclusion: Venolymphatic malformation is one of the most common types of vascular malformations with an overall prevalence of up to 1% in the general population. Although benign, these lesions have a tendency to grow in an infiltrating manner. OK-432, which is the most widely used alternative treatment, showed promising results of regression of malformations, systemic inflammatory response syndrome may be a possible side effect with its use.|
Paula Francezca C Padua, M.D has completed her MD at the age of 27 from St. Luke’s College of Medicine, Quezon City, Philippines, last 2013. She is currently in her 3rd year residency training at the Department of Otolaryngology, Head and Neck Surgery at St. Luke’s Medical Center, Quezon City Philippines.
Email: [email protected]
|PDF | HTML|